Pyrotinib is a novel irreversible epidermal growth factor receptor/human epidermal growth factor receptor 2 (EGFR/HER2) dual tyrosine kinase inhibitor, which can covalently bind to adenosine triphosphate binding sites of intracellular EGFR/HER2 to prevent self-phosphorylation or down-regulation of signal transduction, thereby inhibiting the growth of tumor. This evidence concerns the gene EGFR and neoplasm.